RVMD News and Press, Revolution Medicines Inc. From 07/12/22

Data on Amgen's Lumakras (sotorasib) in combination with Merck's ( NYSE: MRK ) Keytruda (pembrolizumab) and Roche's ( OTCQX:RHHBY ) Tecentriq (atezoliuzumab) will be released on Aug. 7 instead of this month, Reuters reported. Results will be released at the 20...

First-in-class, oral, RAS(ON) Inhibitor being evaluated initially in patients with cancers driven by KRAS G12 mutations Sushil Patel, Ph.D., industry veteran with commercial oncology expertise, elected to board of directors REDWOOD CITY, Calif., June 28, 2022 (GL...

REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in the 43 rd Annual Goldman Sachs Global Healthc...

BofA Securities has initiated Revolution Medicines (NASDAQ:RVMD) at neutral saying that most of the precision oncology company's candidates still need validation. The firm has a $24 price target (~58% upside based on Thursday's close). Analyst Alex Stranahan highlighted that the company's pla...

The following slide deck was published by Revolution Medicines, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Revolution Medicines, Inc. 2022 Q1 - Results - Earnings Call Presentation

Revolution Medicines, Inc. (RVMD) Q1 2022 Earnings Conference Call May 9, 2022 16:30 ET Company Participants David Errington - Senior Vice President of Investor Relations & Corporate Affairs Mark Goldsmith - Chairman & Chief Executive Officer Jack Anders - Senior Vice President of Fin...

Revolution Medicines press release (NASDAQ:RVMD): Q1 GAAP EPS of -$0.78 beats by $0.01. Revenue of $7.58M (-25.2% Y/Y) misses by $1M. Reiterates full year 2022 GAAP net loss to be between $260 million and $290 million. Cash, cash equivalents and marketable securities were $518.8 mil...

Lead RAS(ON) Inhibitor drug candidates RMC-6236 (RAS MULTI ) and RMC-6291 (KRAS G12C ) approaching the clinic RMC-4630-03 Phase 2 trial evaluating RAS Companion Inhibitor RMC-4630 (SHP2) in combination with Lumakras™ (sotorasib) in patients with advanced non-small cell lu...

REDWOOD CITY, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2022 on Monday, May...

Gainers: Spruce Biosciences (SPRB) +7%. ThredUp  (TDUP) +7%. Cellectis  (CLLS) +6%. Revolution Medicines (RVMD) +5%. Ocular Therapeutix (OCUL) +5%. Losers: Trean Insurance Group (TIG) -7%. Lyell Immunopharma (LYEL) -6%. Vivid Seats  (SEAT) -6%. Y-mAbs Therapeutic...